Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study - Concepedia

Concepedia

Publication | Closed Access

Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study

58

Citations

31

References

2000

Year

Dino Amadori, Oriana Nanni, M. Marangolo, P Pacini, Alberto Ravaioli, Andrea Rossi, Angelo Gambi, Giuseppina Catalano, D. Perroni, Emanuela Scarpi,

Journal of Clinical Oncology

Abstract

The results from this randomized clinical study indicate that patients with node-negative, rapidly proliferating tumors significantly benefit from adjuvant CMF.

References

	Year	Citations

Page 1